Perceptive Advisors, a leading life sciences investment firm managing approximately $7 billion in assets, has successfully completed its acquisition of substantially all assets of Synthego, a prominent CRISPR solutions provider. The transaction officially closed on July 18, 2025, following regulatory approval obtained in June.
Strategic Partnership Strengthens CRISPR Innovation
Under the new ownership structure, Synthego will continue operating as normal while maintaining its commitment to delivering high-quality CRISPR products and services to its global clientele. The company's leadership team and dedicated staff remain in place, ensuring seamless continuity in day-to-day operations and customer support.
"We are thrilled to officially complete this transaction and embark on a new chapter with Perceptive Advisors," said Craig Christianson, CEO of Synthego. "This partnership strengthens our financial position and provides us with enhanced resources to accelerate innovation and expand our product portfolio in the months ahead."
The acquisition provides Synthego with a strengthened balance sheet and clear path for expansion, enabling strategic investments to support clients advancing curative therapeutics worldwide. Sam Chawla, Portfolio Manager at Perceptive Advisors, emphasized the firm's commitment to supporting Synthego's growth through well-funded innovation and product launches.
Maintaining American Manufacturing Excellence
Synthego will continue manufacturing its industry-leading guide RNA in Redwood City, California, ensuring this essential component remains produced in the USA. The company's current facilities include two factories, research laboratories, offices, warehousing and logistics infrastructure, supporting the development of CRISPR-based therapies for the global market.
"We are a unique American manufacturer in our field, with a stand-out capability to serve clients advancing curative therapies through the FDA process, and support researchers without tariff-induced price increases," Christianson noted.
Recent Product Expansions Drive Growth
Synthego has demonstrated continued innovation momentum with recent product launches, including a GMP offering of SpCas9 introduced in May 2025. The company further expanded its gene editing options in July with launches of eSpOT-ON and Accubase™ enzymes, along with related guide RNA offerings.
"Our customers' successes inspire us daily, and this partnership ensures we can both expand our offerings and accelerate our mission to deliver the most advanced and reliable CRISPR solutions for their critical work," said Jason Miller, Chief Commercial Officer of Synthego.
Investment Firm's Life Sciences Focus
Founded in 1999 and based in New York, Perceptive Advisors manages a portfolio of approximately $8 billion across more than 80 companies at the forefront of biotechnology and therapeutic development. The firm focuses on supporting the progress of the life sciences industry by identifying opportunities and directing financial resources to the most promising technologies in healthcare.
The acquisition reinforces Synthego's mission to empower scientific discovery through advanced genomic engineering while providing the resources necessary for continued expansion in the rapidly evolving CRISPR therapeutics market.
